| c.-2804 T→C | c.-2265C→T | c.-2004A→G | c.-1896 (ACA)1→(ACA)2 | Cases, n (%) | Controls*, n (%) | p Value† | OR (95% CI)† |
| All participants (n = 682, n = 734 for cases and controls, respectively)‡ | |||||||
| T | C | A | (ACA)1 | 394 (57.8) | 398 (54.21) | RV | RV |
| C | T | G | (ACA)2 | 253 (37.1) | 311 (42.4) | 0.076 | 0.82 (0.66 to 1.02) |
| Participants without a family history of breast cancer (n = 614, n = 712)‡ | |||||||
| T | C | A | (ACA)1 | 360 (58.6) | 388 (54.5) | RV | RV |
| C | T | G | (ACA)2 | 224 (36.5) | 299 (42.0) | 0.062 | 0.81 (0.64 to 1.01) |
| Participants ⩾45 years at first diagnosis and without a family history of breast cancer (n = 312, n = 322)‡ | |||||||
| T | C | A | (ACA)1 | 189 (60.6) | 169 (52.5) | RV | RV |
| C | T | G | (ACA)2 | 105 (33.7) | 146 (45.3) | 0.008 | 0.64 (0.46 to 0.89) |
RV, reference value.
*Cancer cases and control participants that had been genotyped for all four promoter single-nucleotide polymorphisms.
†pValues were obtained using χ2 test, two-tailed and df = 1
‡Haplotype analysis was performed on those participants in which all polymorphisms had been successfully genotyped. Haplotypes were estimated by PLINK (v1.03).